Tenofovir, often combined with emtricitabine, is highly effective as PrEP. Clinical trials and real-world studies have demonstrated its efficacy in reducing the risk of HIV acquisition by up to 99% when taken consistently. This has been a game-changer in HIV prevention strategies, particularly among high-risk groups such as men who have sex with men (MSM), intravenous drug users, and serodiscordant couples.
